FEDERATED HERMES, INC. Trims Arcturus Therapeutics Holdings Inc
FEDERATED HERMES, INC. reduced its stake in Arcturus Therapeutics (ARCT) by 49.21% on Sept. 30, 2026, selling 1.63 million shares at $13.69 each. The firm now holds 1.68 million shares, 5.90% of ARCT's outstanding shares. Arcturus, a clinical-stage mRNA company, has a market cap of $341.93 million and faces valuation concerns, with a GF Value estimate of $2.12, indicating significant overvaluation.
How this was made
The 30-second read
Why it matters
A near‑50% stake reduction by a $70B portfolio manager is a notable signal for ARCT's valuation and liquidity.
Market read
The disclosed trim provides fresh data for traders monitoring biotech micro‑caps and may trigger short‑term price moves.
What to watch
Arcturus' recent Japanese vaccine approval and partnership revenue may offset the fund's concerns.
Background
Fund activity often signals market sentiment for small‑cap biotech names.
Ticker impact
FEDERATED HERMES trimmed its Arcturus stake by 49% to 1.68M shares, signaling reduced confidence.
likely downward pressure as the sell is priced in
A 1.6M‑share reduction from a major holder is material for a micro‑cap biotech and can trigger short‑term price weakness.
Market effects
May dampen sentiment in the clinical‑stage biotech sector as a prominent investor reduces exposure.
Limited to US biotech investors; no broader regional effect.
Low; impact confined to ARCT and similar small‑cap biotech stocks.
Counterpoint
The trim could be a tactical rebalancing rather than a fundamental doubt, presenting a buying opportunity.
Key entities
- institutional investorFEDERATED HERMES, INC.
Pittsburgh‑based investment firm with $69.55B in holdings.
- companyArcturus Therapeutics Holdings Inc
Clinical‑stage mRNA therapeutics developer (NASDAQ: ARCT).
